Details

Autor(en) / Beteiligte

• Nakamoto, Yuji
• Baba, Shingo
• Kaida, Hayato
• Manabe, Osamu
• Uehara, Tomoya

Titel

Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects

Ist Teil von

• Annals of nuclear medicine, 2024, Vol.38 (1), p.10-19

Ort / Verlag

Singapore: Springer Nature Singapore

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Recently, positron emission tomography (PET) with fibroblast activation protein inhibitor (FAPI) has gained significant attention as an advanced tumor diagnostic imaging tool. FAPI PET has a promising potential owing to its ability to accurately depict most malignant tumors. It has an accuracy that is comparable to or surpassing the diagnostic accuracy of PET using 18 F-fluorodeoxyglucose (FDG). Moreover, FAPI PET can identify malignant lesions that may be inconclusive on FDG PET. Beyond its application in neoplastic disorders, there have been encouraging reports suggesting the utility of FAPI PET in non-neoplastic conditions such as respiratory or cardiac diseases. This article aimed to provide a comprehensive overview of the recently published articles investigating FAPI and discuss its clinical utility with an emphasis on its application in tumor diagnostics. Numerous radiopharmaceutical FAPIs, including 18 F- and 68 Ga-labeled compounds, have been developed, and they offer various advantages and applications. With the progress in the FAPI PET synthesis to enhance accumulation and retention in pathological lesions, future studies are expected to provide valuable data on its therapeutic efficacy.